Pharmacokinetics of the sequential metabolites of loteprednol etabonate in rats.
JOURNAL OF PHARMACY AND PHARMACOLOGY(2008)
摘要
Pharmacokinetics, metabolism and excretion of two sequential inactive metabolites of the soft corticosteroid loteprednol etabonate (LE), Delta(1)-cortienic acid etabonate (AE) and Delta(1)-cortienic acid (A), have been investigated in rats. Pharmacolkinetic studies (two-compartment model, 10 mg kg(-1) intravenous bolus of AE or A) found the elimination of both AE (t1/2((beta)), 12.46 +/- 1.18 min; CLtotal, 101.94 +/- 5.80 mL min(-1) kg(-1); and K-el, 0.24 +/- 0.02 min(-1)) and A (t1/2((beta)), 14.62 +/- 0.46 min; CLtotal, 53.80 +/- 1.40 mL min(-1) kg(-1); and K-el, 0.18 +/- 0.02 min(-1)) to be significantly faster than that previously determined for the parent LE (t1/2((beta)), 43.41 +/- 7.58 min; CLtotal, 67.40 +/- 11.60 mL min(-1) kg(-1); and K-el 0.071 +/- 0.024 min(-1)). For metabolism and excretion evaluations, 1 and 10 mg kg(-1) of either AE or A were intravenously administered, and the urine and bile were collected. AE and A rapidly reached their peak concentrations in the bile and urine, and most of them were eliminated within one hour. Total cumulative excretions at 4 h after 1 and 10 mg kg(-1) injections were 85.51 +/- 3.38% and 67.50 +/- 2.67% for AE, and 71.90 +/- 3.72% and 37.73 +/- 2.69% for A in bile; and 4.84 +/- 1.87% and 13.85 +/- 3.27% for AE, and 24.28 +/- 8.44% and 22.35 +/- 1.12% for A in urine, respectively. After AE administration, the excretion of AE was > 90%, and A was < 10% in all cases, indicating that the elimination of AE was much faster than its metabolism (to A). In a manner similar to that seen for LE, dose-dependent elimination was observed both in AE and A. These results suggested that both AE and A were ideal leads for the design of soft steroids based on the inactive metabolite approach.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要